JOURNAL ARTICLE
REVIEW

Targeting synuclein-gamma to counteract drug resistance in cancer

Vinay K Singh, Zongchao Jia
Expert Opinion on Therapeutic Targets 2008, 12 (1): 59-68
18076370

BACKGROUND: Expression of synuclein-gamma (SNCG) protein is elevated in the advanced stages of many types of cancers, including ovarian, lung, liver, esophagus, colon, prostate and, in particular, breast. In breast carcinoma, SNCG is causatively linked to stimulated proliferation, metastasis and drug resistance.

OBJECTIVE: To establish SNCG as a potential therapeutic target and to discuss clinical use of SNCG inhibiting peptide.

METHODS: This review focuses on the plausible mechanisms of SNCG activity, SNCG mediated drug resistance and its inhibition.

RESULTS/CONCLUSION: Evidence based research shows that the aberrant expression of SNCG has a strong correlation with breast cancer progression and poor clinical outcome. A peptide based inhibitor counters activity of SNCG, which may be developed as an adjuvant therapy.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
18076370
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"